HLA Class I in Egyptian patients with Behçet’s disease: new association with susceptibility, protection, presentation and severity of manifestations

References

• Arber N, Klein T, Meiner Z, et al. (1991). Close association of HLA-B51 and B52 in Israeli patients with Behçet’s syndrome. Ann Rheum Dis, 50(6), (June). 351–353. doi:10.1136/ard.50.6.351
   PubMed Web of Science ®Google Scholar
• Assaad-Khalil SH, Clinical G. 1991. Immunological, and biochemical features of 180 Egyptian Patients with Behçet’s Disease. O’Duffy JD, Kokmen E, editor. Behçet’s Disease: basic and Clinical Aspects. New York: Marcel Dekker, 269–277.
   Google Scholar
• Assaad-Khalil SH, Kamel FA, Ismail EA. (1997). Starting a regional registry for patients with Behçet’s Disease in North West Nile Delta Region in Egypt. Hamza M, editor. Behçet’s Disease. Tunis (Tunisia): Pub Adhoua, 173–176.
   Google Scholar
• Bloch SB, Larsen M, Munch IC. (2012). Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol, 153(2), (February). 209–213.e2. doi:10.1016/j.ajo.2011.10.016
   PubMed Web of Science ®Google Scholar
• Cho SB, Cho S, Bang D. (2012). New insights in the clinical understanding of Behçet’s disease. Yonsei Med J, 53(1), (January). 35–42. doi:10.3349/ymj.2012.53.1.35
   PubMed Web of Science ®Google Scholar
• Choukri F, Chakib A, Himmich H, et al. (2001). HLA-B*51 and B*15 alleles confer predisposition to Behçet’s disease in Moroccan patients. Hum Immunol, 62(2), (February). 180–185.
   PubMed Web of Science ®Google Scholar
• Criteria for Diagnosis of Behçet’s Disease. (1990). International Study Group for Behçet’s disease. Lancet (London, England), 335(8697), (May 5). 1078–1080.
   PubMed Web of Science ®Google Scholar
• de Chambrun P, Wechsler M,B, Geri G, et al. (2012). New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev, 11(10), (August). 687–698. doi:10.1016/j.autrev.2011.11.026
   PubMed Web of Science ®Google Scholar
• de Menthon M, Lavalley MP, Maldini C, et al. (2009). HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum, 61(10), (October 15). 1287–1296. doi:10.1002/art.24642
   PubMed Web of Science ®Google Scholar
• Deniz R, Tulunay-Virlan A, Ozdemir FT, et al. (2017). Th17-inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet’s Disease. Immunol Invest, 46(5), (July 4). 518–525. doi:10.1080/08820139.2016.1267204
   PubMed Web of Science ®Google Scholar
• El Menyawi MM, Raslan HM, Edrees A. (2009). Clinical features of Behcet’s disease in Egypt. Rheumatol Int, 29(6), (April). 641–646. doi:10.1007/s00296-008-0741-2
   PubMed Web of Science ®Google Scholar
• El-Hagrassy N, El-Chennawi F, Zaki ME-S, et al. (2010). HLA class I and class II HLA DRB profiles in Egyptian children with rheumatic valvular disease. Pediatr Cardiol, 31(5), (July). 650–656. doi:10.1007/s00246-010-9663-3
   PubMed Web of Science ®Google Scholar
• Gourley IS, Kearns J, McKeen M, et al. (2002). . HLA class I typing of volunteers for a bone marrow registry: QC Analysis by DNA-based methodology identifies serological typing discrepancies in the assignment of HLA-A and B antigens. Tissue Antigens, 59(3), (March). 211–215. doi:10.1034/j.1399-0039.2002.590305.x
   PubMedGoogle Scholar
• Gül A. (2014). Genetics of Behçet’s Disease: lessons learned from genomewide association studies. Curr Opin Rheumatol, 26(1), (January). 56–63. doi:10.1097/BOR.0000000000000003
   PubMed Web of Science ®Google Scholar
• Gül A, Uyar FA, Inanç M, et al. (2002). A weak association of HLA-B*2702 with Behçet’s disease. Genes Immun, 3(6), (September). 368–372. doi:10.1038/sj.gene.6363863
   PubMed Web of Science ®Google Scholar
• Gül A, Uyar FA, Inanc M, et al. (2001). Lack of Association of HLA-B*51 with a severe disease course in Behçet’s disease. Rheumatology (Oxford), 40(6), (June). 668–672. doi:10.1093/rheumatology/40.6.668
   PubMed Web of Science ®Google Scholar
• Hamzaoui A, Houman MH, Massouadia M, et al. (2012). Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet’s disease in Tunisian patients. Eur J Intern Med, 23(4), (June). 347–349. doi:10.1016/j.ejim.2011.12.011
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D. et al. (2008). EULAR recommendations for the management of Behçet disease. Ann Rheum Dis, 67(12), (December). 1656–1662. doi:10.1136/ard.2007.080432
   PubMed Web of Science ®Google Scholar
• Hughes T, Coit P, Adler A. et al. (2013). Identification of multiple independent susceptibility loci in the HLA region in Behçet’s disease. Nat Genet, 45(3), (March). 319–324. doi:10.1038/ng.2551
   PubMed Web of Science ®Google Scholar
• Itoh Y, Inoko H, Kulski JK, et al. (2006). Four-digit allele genotyping of the HLA-A and HLA-B Genes in Japanese patients with Behcet’s disease by a PCR-SSOP-Luminex method. Tissue Antigens, 67(5), (May). 390–394. doi:10.1111/tan.2006.67.issue-5
   PubMedGoogle Scholar
• Jennette JC. (2013). Overview of the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol, 17(5), (October). 603–606. doi:10.1007/s10157-013-0869-6
   PubMed Web of Science ®Google Scholar
• Kamal A, Gamal SM, Elgengehy FT, et al. (2016). Association of VDR Apai and Taqi gene polymorphisms with the risk of scleroderma and Behçet’s Disease. Immunol Invest, 45(6), (August). 531–542. doi:10.1080/08820139.2016.1180302
   PubMed Web of Science ®Google Scholar
• Krause L, Köhler A-K, Altenburg A, et al. (2009). Ocular involvement is associated with HLA-B51 in adamantiades-Behçet’s disease. Eye (Lond), 23(5), (May). 1182–1186. doi:10.1038/eye.2008.177
   PubMed Web of Science ®Google Scholar
• Lennikov A, Alekberova Z, Goloeva R. et al. (2015). Single center study on ethnic and clinical features of Behcet’s disease in Moscow, Russia. Clin Rheumatol, 34(2), (February). 321–327. doi:10.1007/s10067-013-2442-9
   PubMed Web of Science ®Google Scholar
• Maldini C, LaValley MP, Cheminant M, et al. (2012). Relationships of HLA-B51 or B5 genotype with Behçet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology, 51(5), (May 1). 887–900. doi:10.1093/rheumatology/ker154
   PubMed Web of Science ®Google Scholar
• Meguro A, Inoko H, Ota M. et al. (2010). Genetics of Behçet Disease inside and outside the MHC. Ann Rheum Dis, 69(4), (April). 747–754. doi:10.1136/ard.2009.108571
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16(3), (February 11). 1215. doi:10.1093/nar/16.3.1215
   PubMed Web of Science ®Google Scholar
• Montes-Cano MA, Conde-Jaldón M, García-Lozano JR. et al. (2013). HLA and Non-HLA Genes in Behçet’s disease: a multicentric study in the Spanish population. Arthritis Res Ther, 15(5), (October 4). R145. doi:10.1186/ar4328
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Farag RE, Arafa MM, et al. (2010). Association of human leucocyte antigen class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. Scand J Immunol, 72(6), (December). 548–553. doi:10.1111/sji.2010.72.issue-6
   PubMed Web of Science ®Google Scholar
• Ombrello MJ, Kirino Y, de Bakker PIW, et al. (2014). Behçet Disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A, 111(24), (June 17). 8867–8872. doi:10.1073/pnas.1406575111
   PubMed Web of Science ®Google Scholar
• Shahram F, Davatchi F, Nadji A, et al. (2003). HLA-B51 frequency in Iranian patients with Behçet’s disease. Adv Exp Med Biol, 528, 229–230.
   PubMed Web of Science ®Google Scholar
• Soto-Vega E, García-Muñoz R, Richaud-Patin Y, et al. (2004). Class I and class II MHC polymorphisms in Mexican patients with Behçet’s Disease. Immunol Lett, 93(2–3), (May 15). 211–215. doi:10.1016/j.imlet.2004.03.017
   PubMed Web of Science ®Google Scholar
• Svejgaard A, Ryder LP. (1994). HLA and disease associations: detecting the strongest association. Tissue Antigens, 43(1), (January). 18–27. doi:10.1111/tan.1994.43.issue-1
   PubMedGoogle Scholar
• Takeuchi M, Kastner DL, Remmers EF. (2015). The immunogenetics of Behçet’s Disease: a comprehensive review. J Autoimmun, 64(November), 137–148. doi:10.1016/j.jaut.2015.08.013
   PubMedGoogle Scholar
• Wildner G, Thurau SR. (1994). Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol, 24(11), (November). 2579–2585. doi:10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. (1990). . A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med, 322(5), (February 1). 281–285. doi:10.1056/NEJM199002013220501
   PubMed Web of Science ®Google Scholar